A new AI platform is changing how the pharmaceutical industry develops drugs and reduces the cost of clinical trials.
Developed by GATC Health, the technology predicts with 87% accuracy whether a drug will be safe and effective in trials. This innovation has drawn support from Lloyd’s of London’s insurance syndicate, Medical and Commercial International Limited (MCI), which will fund and insure trials for drugs the AI deems likely to succeed.
Drug development is expensive and slow, costing around $1 billion and taking 10-15 years per successful medication. This is because 90% of drugs fail during clinical trials, according to experts. However, GATC’s platform could significantly cut costs and boost success rates, transforming the industry.
The technology, called “Multiomics Advanced Technology” (MAT), uses AI to simulate human biology and predict how a drug will interact with the body, including potential side effects. “It takes the risk out of running clinical trials,” said William Padula, a pharmaceutical economics expert at USC.
By identifying key biological targets and creating compounds to address diseases, MAT could revolutionize drug discovery. “We’re finding the ‘locks’ in the body that cause diseases and creating the ‘keys’ to fix them,” explained Tyrone Lam, COO of GATC.
GATC is also developing its own drugs, including a non-addictive treatment for opioid dependence. This medication aims to repair the brain areas affected by addiction and is set to begin human trials soon.
The AI platform has already gained interest from 90 biotech companies for screening their drug pipelines. Experts believe it could lower drug prices for patients in the future by making development more efficient.
“This could lead to cheaper drugs for patients by reducing the high costs of clinical trials,” said Padula.
GATC’s innovation represents a major shift in drug development, with the potential to improve outcomes for patients worldwide.
Source: newsweek
